이상반응 보고
| VAERS ID | 2247531 |
|---|---|
| 성별 | 남성 |
| 나이 | 23세 |
| 주 코드 | FR |
| 제약회사 | MODERNA |
| 로트 번호 | |
| 예방접종 횟수 | 3 |
| 접종일 | 2022-04-01 |
| 발병일 | 2022-04-04 |
| 상태 | 입원 |
증상
- 가슴 불편함(Chest discomfort)
- 호흡곤란(Dyspnoea)
- 가슴 통증(Chest pain)
이환 중 질병
지병
Comments: Past medical history included cellulitis and asthma.
기타 의료
이전 예방접종
알레르기
임상 검사
증상 상세
Dyspnea; Chest tightness; Chest pain; This case was received (no reference has been entered for a on 11-Apr-2022 and was forwarded to Moderna on 13-Apr-2022.
This regulatory authority case was reported by a health care professional and describes the occurrence of DYSPNOEA (Dyspnea), CHEST DISCOMFORT (Chest tightness) and CHEST PAIN (Chest pain) in a 23-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.
Past medical history included cellulitis and asthma.
On 01-Apr-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.
On 04-Apr-2022, the patient experienced DYSPNOEA (Dyspnea) (seriousness criterion hospitalization), CHEST DISCOMFORT (Chest tightness) (seriousness criterion hospitalization) and CHEST PAIN (Chest pain) (seriousness criterion hospitalization).
At the time of the report, DYSPNOEA (Dyspnea), CHEST DISCOMFORT (Chest tightness) and CHEST PAIN (Chest pain) was resolving.
For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Concomitant product use was not provided by the reporter.
On 01-Apr-2022, the patient received third dose of Moderna vaccine in the clinic.
On 04-Apr-2022, he had wheezing when climbing stairs.
On 05-Apr-2022, in the evening, he felt chest pain and chest tightness, so he went to hospital for emergency consultations and treatments.
GCS: E4M6V5; body temperature: 36.
9 degree celsius; blood oxygen: 95 percentage; pulse: 96 beats per minute (BPM); respiration: 20 times/min; blood pressure: 179/116 mmHg; white blood cells (WBC): 7820/UL; abnormal test values: 53.
9 percentage for neutrophils, and 0.
41 mg/dl for c-reactive protein (CRP); electrocardiogram (ECG): no abnormality and chest X-ray: no abnormality.
The patient was hospitalized after emergency injection of N/S 500 ml and Nifedipine 10 mg/capsule at 1 capsule SL.
During hospitalization, acetaminophen 500 mg/capsule at 1 capsule QID, chlorzoxazone 200 mg/capsule at 1 capsule TID, and amlodipine 5 mg/capsule at 1 capsule QD were used.
On 07-Apr-2022, the symptoms were improved, and the patient was discharged with acetaminophen 500 mg/capsule at 1 capsule TID and chlorzoxazone 200 mg/capsule at 1 capsule TID.
Company comment: This regulatory authority case concerns a 23-year-old male patient, with medical history of asthma, who experienced the serious (due to hospitalization) unexpected events of DYSPNOEA, CHEST DISCOMFORT and CHEST PAIN.
The event DYSPNOEA occurred on the same day of third dose of mRNA-1273 vaccine, and the other events developed on the following day of vaccination.
No details about previous doses were provided.
According to the narrative of the source document, he was admitted after receiving Nifedipine as treatment.
A physical examination, laboratory tests, an electrocardiogram and a chest X-ray were performed with normal results, and continued treatment with acetaminophen, chlorzoxazone, and amlodipine.
The symptoms were improved, and the patient was discharged with acetaminophen and chlorzoxazone.
The history of asthma remains a confounder for dyspnoea and chest discomfort.
The benefit-risk relationship of the mRNA-1273 is not affected by this report.
The seriousness was assessed as per regulatory authority report.
; Sender's Comments: This regulatory authority case concerns a 23-year-old male patient, with medical history of asthma, who experienced the serious (due to hospitalization) unexpected events of DYSPNOEA, CHEST DISCOMFORT and CHEST PAIN.
The event DYSPNOEA occurred on the same day of third dose of mRNA-1273 vaccine, and the other events developed on the following day of vaccination.
No details about previous doses were provided.
According to the narrative of the source document, he was admitted after receiving Nifedipine as treatment.
A physical examination, laboratory tests, an electrocardiogram and a chest X-ray were performed with normal results, and continued treatment with acetaminophen, chlorzoxazone, and amlodipine.
The symptoms were improved, and the patient was discharged with acetaminophen and chlorzoxazone.
The history of asthma remains a confounder for dyspnoea and chest discomfort.
The benefit-risk relationship of the mRNA-1273 is not affected by this report.
The seriousness was assessed as per regulatory authority report.